Fixed-Dose ADHD Tablet with pH-Sensitive Erodible Layers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ADHD treatments face challenges with administration of multiple-active agent oral medications, particularly in achieving controlled release profiles and patient compliance, as existing methods struggle to provide individually tailored and effective dosing for both stimulants and non-stimulants.
Innovation Solution
The development of oral drug dosage forms comprising erodible materials for ADHD non-stimulants and stimulants, embedded in a substrate, which release the medications according to desired profiles, such as sustained or immediate release, using multi-layered structures and specific formulations like hydroxyl propyl cellulose and vinylpyrrolidone-vinyl acetate copolymer, to achieve controlled pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple-active agent oral medications are used for ADHD treatment, then treatment efficacy is improved, but administration complexity and patient compliance deteriorate
Solution Approach 1:
The patent combines multiple ADHD medications (stimulant and non-stimulant) into a single fixed-dose oral tablet, merging what would traditionally require separate pills into one unified dosage form. This resolves the contradiction by maintaining the therapeutic benefits of multiple agents while simplifying administration to a single pill, thereby improving patient compliance without sacrificing treatment efficacy.
Solution Approach 2:
The single oral tablet performs multiple functions by delivering both stimulant and non-stimulant medications simultaneously, along with incorporating pH-sensitive materials that provide controlled release functionality. This multi-functional design allows one medication form to replace multiple separate medications, resolving the administration complexity issue while maintaining comprehensive treatment efficacy.
2Manufacturing precision
If controlled release profiles are implemented for ADHD medications, then dosing precision is improved, but manufacturing complexity deteriorates
Solution Approach 1:
The patent employs pH-sensitive materials that change their release characteristics based on pH parameters along the gastrointestinal tract. By utilizing the natural pH gradient (acidic stomach to alkaline intestine), the formulation achieves controlled release profiles without requiring complex mechanical release mechanisms, thereby improving dosing precision while keeping manufacturing complexity manageable.
Solution Approach 2:
The pH-sensitive polymer acts as an intermediary between the medication and the gastrointestinal environment, mediating the release of drugs based on pH conditions. This intermediary mechanism enables precise control over when and how medications are released without requiring complex manufacturing processes, as the pH-sensitive material naturally responds to physiological conditions.
3Ease of operation
If fixed-dose combination medications are produced, then patient compliance is improved, but flexibility in dosing individual agents deteriorates
Solution Approach 1:
The patent incorporates pH-sensitive materials that dynamically adjust drug release based on gastrointestinal pH conditions. This dynamic behavior allows the fixed-dose combination to adapt its release profile to physiological variations, providing a degree of flexibility within the fixed-dose framework. The system maintains patient compliance through single-pill administration while dynamically responding to individual physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These dosage forms enhance dosing accuracy, treatment efficacy, and patient compliance by providing controlled release profiles for ADHD medications, reducing adverse events and costs, and allowing for personalized dosing tailored to individual needs.
Implementation Method 1
an erodible non-stimulant material admixed with an ADHD non-stimulant... upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a sustained release profile
Implementation Method 2
The oral drug dosage forms described herein may be designed and produced to provide a desired drug release profile... erosion of an erodible non-stimulant material admixed with an ADHD non-stimulant
Data Source
AI summary
The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.